Predictive value of the <scp>CLL</scp>‐<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemo‐immunotherapy as first‐line treatment

Gentile, Massimo; Shanafelt, Tait D.; Mauro, Francesca Romana; Reda, Gianluigi; Rossi, Davide; Laurenti, Luca; Principe, Maria Ilaria Del; Cutrona, Giovanna; Angeletti, Ilaria; Coscia, Marta; Herishanu, Yair; Chiarenza, Annalisa; Molica, Stefano; Ciolli, Stefania; Goldschmidt, Neta; Angrilli, Francesco; Giordano, Annamaria; Rago, Angela; Bairey, Osnat; Tripepi, Giovanni; Chaffee, Kari G.; Sameer, Parikh A.; Vigna, Ernesto; Zirlik, Katja; Shvidel, Lev; Innocenti, Idanna; Recchia, Anna Grazia; Raimondo, Francesco Di; Poeta, Giovanni Del; Cortelezzi, Agostino; Neri, Antonino; Ferrarini, Manlio; Gaïdano, Gianluca; Kay, Neil E.; Polliack, Aaron; Foà, Robin; Morabito, Fortunato

doi:10.1111/ejh.13149

Cited by 10 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with the nomogram proposed by the MDACC group, the CLL-IPI included cytogenetic abnormalities and was confirmed higher prognostic value in both OS and TTFT for newly diagnosed patients [12,98,99]. It predicts both PFS and OS and can be used in varieties of CIT approaches [100]. However, IGHV mutational status was only available in 10.1% CLL patients in 2014 in the United States [53].…”

Section: Risk Staging Systems In Cllmentioning

confidence: 94%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia with high heterogeneity in the western world. Thus, investigators identified a number of prognostic biomarkers and scoring systems to guide treatment decisions and validated them in the context of immunochemotherapy. A better understanding of prognostic biomarkers, including serum markers, flow cytometry outcomes, IGHV mutation status, microRNAs, chromosome aberrations and gene mutations, have contributed to prognosis in CLL. Del17p/ TP53 mutation, NOTCH1 mutation, CD49d, IGHV mutation status, complex karyotypes and microRNAs were reported to be of predictive values to guide clinical decisions. Based on the biomarkers above, classic prognostic models, such as the Rai and Binet staging systems, MDACC nomogram, GCLLSG model and CLL-IPI, were developed to improve risk stratification and tailor treatment intensity. Considering the presence of novel agents, many investigators validated the conventional prognostic biomarkers in the setting of novel agents and only TP53 mutation status/del 17p and CD49d expression were reported to be of prognostic value. Whether other prognostic indicators and models can be used in the context of novel agents, further studies are required.

show abstract

Section: Risk Staging Systems In Cllmentioning

confidence: 94%

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

2020

View full text Add to dashboard Cite

show abstract

“…52 The CLL-IPI was validated in an independent cohort of patients with newly diagnosed CLL and is useful for predicting TTFT and risk of progression in patients receiving first-line chemoimmunotherapy. 60 CLL-IPI stratifies patients into 4 risk groups (low, intermediate, high, and very high) with significantly different OS. The 5-year OS rates were 93%, 79%, 63%, and 23%, respectively for the 4 risk groups.…”

Section: Prognostic Modelsmentioning

confidence: 99%

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

Wierda,

Brown,

Abramson

et al. 2024

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.

show abstract

“…either del(17p) or TP53 mutations] based on the absence of a statistical association between the presence of the sole del(17p) versus the sole TP53 mutation or between the presence of a single marker versus the presence of both. CLL-IPI has been widely confirmed for patients undergoing chemo-immunotherapy [16][17][18][19].…”

Section: Chemo-immunotherapymentioning

confidence: 99%

TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors

Morabito

Gentile²,

Monti

et al. 2020

Expert Opinion on Investigational Drugs

Self Cite

View full text Add to dashboard Cite

Introduction. Patients with TP53 dysfunction, assessed by del(17p) or TP53 mutations, respond poorly to chemo-immunotherapy and fare better with the new therapies (BCR and BCL-2 inhibitors); however, it is unclear whether their response is similar to that of patients without anomalies or whether there is currently an adequate determination of TP53 dysfunction. Area covered.A literature search was undertaken on clinical trials and real-world experience data on patients with TP53 dysfunction treated with different protocols. Moreover, data on the TP53 biological function and on the tests currently employed for its assessment were reviewed. Expert opinion.Although TP53 dysfunction has less negative influence on the new biological therapies, patients with these alterations, particularly those with biallelic inactivation of TP53, have a worst outcome with these therapies than those without alterations. At present, a determination of TP53, particularly with next generation sequencing (NGS) methodologies, may be sufficient for the identifications of the patients unsuitable for chemo-immunotherapy, although integration with del(17p) would be advisable. For the future, more extensive determinations of the TP53 status, including functional assays, may become part of the current armamentarium for a better patient stratification and treatment with newer protocols.

show abstract

Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment

Cited by 10 publications

References 14 publications

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors

Contact Info

Product

Resources

About